MedTrace Logo

Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

NCT01324336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-01-05

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).

Conditions

Interventions

DRUG

6-Mercaptopurine

75 mg/m2/dose/day

Sponsors & Collaborators

  • Midwest Cancer Alliance

    collaborator UNKNOWN

  • Children's Mercy Hospital Kansas City

    lead OTHER

Principal Investigators

  • Kathleen A Neville, MD, MS · The Children's Mercy Hospitals and Clinics

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324336 on ClinicalTrials.gov